Alessandro Fatatis

Drexel University College of Medicine
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (9)

Year:

2026

Particle size distributions obtained by Zeta View of sEVs derived from WT and TR mouse plasma (A-B) Zetaview Nanoparticle tracking analysis measurement of size distribution and concentration of iodixanol density gradient isolated md-sEVs derived from (A) WT or (B) TR mouse plasma.

Year:

2025

Particle size distributions obtained by Nanoparticle tracking analysis (NTA) of sEVs derived from β1 FF or β1 FF TR mouse plasma (A-B) NTA measurement of size distribution and concentration of iodixanol density gradient isolated md-sEVs derived from (A) β1 FF or (B) β1 FF TR mouse plasma.

Year:

2025

Validation of STEAP1 antibody specificity using siRNA (A) Immunoblotting (IB) of STEAP1, androgen receptor (AR), and β-Actin expression in C4-2 cells transfected with a SMARTpool siRNA against STEAP1 (siSTEAP1) or scramble siRNA (scramble) for 48 (right) and 96 hours (left). (B) IB of STEAP2 and (C) STEAP4 expression in C4-2 cells transfected with SMARTpool siRNA against STEAP1 (siSTEAP1) or scrambled siRNA (siScramble) for 48 hours. Vinculin is used as loading control.

Year:

2025

STEAP expression changes with DHT dose response Relative mRNA expression of (A) STEAP2 and STEAP4 in LNCaP cells and (B) STEAP1, STEAP2, STEAP4 and KLK3 expression in C42 cells treated with 0 nM (DMSO), 0.1 nM, 1 nM, and 10 nM DHT for 24 hours in regular growth or CSS conditions. P-values were calculated using two-way ANOVA followed by post-hoc Tukey test for multiple comparisons.

Year:

2025

The six-transmembrane epithelial antigen of the prostate (STEAP; STEAP1 and STEAP2) metalloreductases are therapeutic targets for advanced prostate cancer, and their expression has been linked to androgen receptor (AR) signaling; however, the regulatory mechanism and functions of STEAP1 and STEAP2 in prostate cancer progression remain elusive. In this study, we explore how in vitro androgen modulation and AR inhibition influence the expression of STEAP family members in cell lines with varying reliance on androgen signaling. Our data show that in response to androgen deprivation, STEAP1 and STEAP2 exhibit elevated transcript levels, whereas STEAP4 levels are reduced, mirroring the expression profile of kallikrein-related peptidase 3 ( KLK3 ). As STEAP1 and STEAP2 are implicated in the exocytic pathway, we evaluated expression profiles in small extracellular vesicles (sEV) released from prostate cancer cells and in circulating sEVs. STEAP1, but not STEAP2, is upregulated in sEVs from AR-negative cells, which express low cellular STEAP1, and AR-positive cells, which express high cellular STEAP1. These results indicate selective packaging of STEAP1 in prostate cancer cell–derived sEVs, irrespective of AR status and cellular STEAP1 expression levels. Finally, ex vivo analysis of circulating sEVs from genetically engineered mice carrying prostate cancer shows that STEAP1 is found in the sEV cargo and that its levels are independent of protumorigenic β1 integrin expression in the prostatic epithelium. Implications: Understanding how androgen dependence affects STEAP1 expression in both tumor cells and sEVs across distinct disease stages will illuminate the clinical benefit of combinatorial AR and STEAP1-directed therapies and inform the optimal placement of STEAP1 targeting within the prostate cancer disease continuum.

Year:

2025

STEAP mRNA expression in response to AR antagonist Relative mRNA expression of STEAP1, STEAP2, STEAP4 and KLK3 in (A) LNCaP cells, (B) C4-2 cells and (C) 22Rv1 cells treated with indicated doses of enzalutamide for 24 hours in regular growth or CSS conditions. KLK3 is the positive control for AR signaling response. Experiments were performed in n = 3 or n = 4. The values are presented as replicates with error bars representing mean ± SEM. P-values were calculated using Two-Way ANOVA with a 95% confidence interval threshold followed by post-hoc Dunnett test for multiple comparisons.

Year:

2025

Correlation of STEAP1 expression with AR and AR target genes in primary and metastatic PCa cohorts Gene expression correlations of STEAP1, AR and canonical AR target genes KLK2, KLK3, KLK15, NKX3-1 and TMPRSS2. mRNA expression from Z-scores quantified by RNA Seq V2 RSEM for primary and FPKM for metastatic. (A) Primary Prostate Adenocarcinoma (TCGA Firehose Legacy) and (B) Metastatic Prostate Adenocarcinoma (SU2C/PCF Dream Team, 2019). (C) RNA-sequencing values from 210 mCRPC patient biopsies. Correlations between Z-scores of AR activity (top row) and KLK3 (bottom row) with STEAP1 and STEAP2. AR activity was measured as the mean Z-score of 7 AR target genes.

Year:

2025

We report the inverse association between the expression of androgen receptor (AR) and IL1β in a cohort of patients with metastatic castration-resistant prostate cancer. We also discovered that AR represses the IL1β gene by binding an androgen response element half-site located within the promoter, which explains the IL1β expression in AR-negative (ARNEG) cancer cells. Consistently, androgen depletion or AR-pathway inhibitors (ARI) derepressed IL1β in AR-positive cancer cells, both in vitro and in vivo. The AR transcriptional repression is sustained by histone deacetylation at the H3K27 mark in the IL1β promoter. Notably, patients’ data suggest that DNA methylation prevents IL1β expression, even if the AR-signaling axis is inactive. Our previous studies show that secreted IL1β supports metastatic progression in mice by altering the transcriptome of tumor-associated bone stroma. Thus, in patients with prostate cancer harboring ARNEG tumor cells or treated with androgen-deprivation therapy/ARIs, and with the IL1β gene unmethylated, IL1β could condition the metastatic microenvironment to sustain disease progression. Significance: IL1β plays a crucial role in promoting skeletal metastasis. The current standard of care for patients with prostate cancer inhibits the AR-signaling axis in tumor cells and will consequently unleash IL1β production. Thus, hormonal deprivation and AR inhibitors should be combined with targeting IL1β signaling, and screening for DNA methylation on the IL1β locus will identify patients that benefit the most from this approach.

Year:

2022

Collaborators (6)

michela perego

Research Assistant Professor

The Wistar Institute

UNITED STATES
View details

Lucia Languino

Prof

Thomas Jefferson University

UNITED STATES
View details

Ricardo Santos

Thomas Jefferson University

UNITED STATES
View details

David Goodrich

Distinguished Professor of Oncology

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Kevin Kelly

Professor, Associate Director of Research, SKCC

Thomas Jefferson University

UNITED STATES
View details

Matthew Schiewer

Assistant Professor

Thomas Jefferson University

UNITED STATES
View details